ArticleJournal of the Pediatric Orthopaedic Society of North America2026
Concentrated Bone Marrow Aspirate With Extracellular Matrix Grafting for Osteochondral Lesions of the Talus in Pediatric and Adolescent Patients.
Article in Journal of the Pediatric Orthopaedic Society of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment of osteochondral lesions of the talus (OLTs) can be challenging due to difficult access/visualization and limited healing capacity. While outcomes after concentrated extracellular matrix combined with bone marrow aspirate concentrate (ECM-BMAC) have been reported for adult populations, its use in pediatric/adolescent patients has not been thoroughly examined. This case series assesses clinical outcomes of ECM-BMAC grafting for young patients with OLTs. Methods: All patients ≤18 years of age presenting to two surgeons between 2016 and 2024 who underwent primary surgery with ECM-BMAC for an OLT with minimum 1-year clinical follow-up were included. Preoperative primary sport, concomitant procedures, lesion size/location, postoperative complications, requirement for reoperation, and postoperative sports clearance were recorded. Various Patient-Reported Outcomes Measurement Information System (PROMIS) scales were obtained from the medical record, where available at minimum 9 months postoperatively. Descriptive statistics were calculated, and patient-reported outcomes (PROs) were compared using Wilcoxon signed-rank tests. Results: Sixteen patients with unilateral OLTs were included in this study. Fifty-six percent of patients were female with a mean age of 14.3 ± 1.8 years (95% confidence interval [CI]: 13.4-15.3) at surgery, and the mean clinical follow-up was 32.8 ± 19.5 months (95% CI: 22.4-43.1). Lesions most commonly affected the medial talar dome (81%) and had mean size and depth of 103.9 ± 52.2 mm Conclusions: High sports clearance rates and improved PROMIS pain scores with low rates of reoperation at short-term follow-up provide early evidence that arthroscopic management with ECM-BMAC can achieve favorable outcomes for treatment of OLTs in pediatric/adolescent patients. Key Concepts: (1)A detailed surgical technique for the arthroscopic management of osteochondral lesions of the talus (OLTs) in young patients using extracellular matrix combined with bone marrow aspirate concentrate (ECM-BMAC) is provided to achieve a more hyaline-like cartilage.(2)High sports clearance rates and improved Patient-Reported Outcomes Measurement Information System (PROMIS) pain scores are observed at short-term after arthroscopic management of OLTs in pediatric/adolescent patients with ECM-BMAC.(3)ECM-BMAC for OLTs is associated with low rates of re-operation. Level of Evidence: IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.